Richy Agajanian, M.D.March 7, 2019

FDA 483 - Richy Agajanian, M.D. - March 07, 2019

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Richy Agajanian, M.D.

Record Details

An FDA inspection of Richy Agajanian, M.D. in Whittier, CA, a clinical investigator, revealed a significant issue regarding the conduct of an investigation. The firm failed to adhere to the signed statement of investigator and investigational plan, specifically concerning the reporting of adverse events and the review and maintenance of subject diaries. This indicates a failure to follow study protocols for clinical trials.

Company: Richy Agajanian, M.D.
Inspection Date: March 7, 2019
Product Type: Drugs
Office: Division of Pharmaceutical Quality Operations IV
Person: Denise L. Burosh (Bioresearch Monitoring Specialis)

Open in Dashboard

ID · 5617656d-f03d-464a-8819-ccae493d701b